Title: Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real‐world retrospective study from Spain and systematic review of the published data
Abstract: Journal of the European Academy of Dermatology and VenereologyEarly View LETTER TO THE EDITOR Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data J. Cañueto, Corresponding Author J. Cañueto [email protected] orcid.org/0000-0003-0037-7353 Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain Correspondence J. Cañueto, Servicio de Dermatología, Complejo Asistencial Universitario de Salamanca, Paseo San Vicente, 58-182, 37007 Salamanca, Spain. Grupo IBSAL CANC-30: Dermato-oncology, Salamanca, Spain. Email: [email protected]Search for more papers by this authorE. Muñoz-Couselo, E. Muñoz-Couselo Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainSearch for more papers by this authorC. Cardona-Machado, C. Cardona-Machado Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainSearch for more papers by this authorS. Becerril-Andrés, S. Becerril-Andrés Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainSearch for more papers by this authorJ. Martín-Vallejo, J. Martín-Vallejo Departamento de Estadística, Universidad de Salamanca y Unidad de Bioestadistica del IBSAL, Salamanca, SpainSearch for more papers by this authorC. Serra-Guillén, C. Serra-Guillén Dermatology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, SpainSearch for more papers by this authorA. Soria, A. Soria Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, SpainSearch for more papers by this authorJ. J. Serrano-Domingo, J. J. Serrano-Domingo Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, SpainSearch for more papers by this authorC. Ortiz-Velez, C. Ortiz-Velez Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainSearch for more papers by this authorJ. Lostes, J. Lostes Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainSearch for more papers by this authorA. García-Castaño, A. García-Castaño Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, SpainSearch for more papers by this authorS. Puig, S. Puig orcid.org/0000-0003-1337-9745 Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, IDIBAPS, CIBERER, Barcelona, SpainSearch for more papers by this authorR. Fernández de Misa, R. Fernández de Misa Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, SpainSearch for more papers by this authorJ. Medina, J. Medina Medical Oncology, Hospital Virgen de la Salud, Toledo, SpainSearch for more papers by this authorC. Aguado, C. Aguado Medical Oncology, Hospital Clínico San Carlos, Madrid, SpainSearch for more papers by this authorP. Ayala de Miguel, P. Ayala de Miguel Medical Oncology, Hospital San Pedro de Alcántara, Caceres, SpainSearch for more papers by this authorI. Navarro-Navarro, I. Navarro-Navarro Dermatology, Hospital Universitario Puerta del Mar, Cádiz, SpainSearch for more papers by this authorE. Masferrer, E. Masferrer Dermatology, Hospital Universitari Mútua Terrassa, Barcelona, SpainSearch for more papers by this authorM. Delgado, M. Delgado Medical Oncology, Hospital Universitario Clínico San Cecilio, Granada, SpainSearch for more papers by this authorL. Bellido-Hernández, L. Bellido-Hernández Medical Oncology, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainSearch for more papers by this authorO. Sanmartin, O. Sanmartin Dermatology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, SpainSearch for more papers by this author J. Cañueto, Corresponding Author J. Cañueto [email protected] orcid.org/0000-0003-0037-7353 Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain Correspondence J. Cañueto, Servicio de Dermatología, Complejo Asistencial Universitario de Salamanca, Paseo San Vicente, 58-182, 37007 Salamanca, Spain. Grupo IBSAL CANC-30: Dermato-oncology, Salamanca, Spain. Email: [email protected]Search for more papers by this authorE. Muñoz-Couselo, E. Muñoz-Couselo Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainSearch for more papers by this authorC. Cardona-Machado, C. Cardona-Machado Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainSearch for more papers by this authorS. Becerril-Andrés, S. Becerril-Andrés Dermatology, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainSearch for more papers by this authorJ. Martín-Vallejo, J. Martín-Vallejo Departamento de Estadística, Universidad de Salamanca y Unidad de Bioestadistica del IBSAL, Salamanca, SpainSearch for more papers by this authorC. Serra-Guillén, C. Serra-Guillén Dermatology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, SpainSearch for more papers by this authorA. Soria, A. Soria Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, SpainSearch for more papers by this authorJ. J. Serrano-Domingo, J. J. Serrano-Domingo Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, SpainSearch for more papers by this authorC. Ortiz-Velez, C. Ortiz-Velez Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainSearch for more papers by this authorJ. Lostes, J. Lostes Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainSearch for more papers by this authorA. García-Castaño, A. García-Castaño Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, SpainSearch for more papers by this authorS. Puig, S. Puig orcid.org/0000-0003-1337-9745 Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, IDIBAPS, CIBERER, Barcelona, SpainSearch for more papers by this authorR. Fernández de Misa, R. Fernández de Misa Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, SpainSearch for more papers by this authorJ. Medina, J. Medina Medical Oncology, Hospital Virgen de la Salud, Toledo, SpainSearch for more papers by this authorC. Aguado, C. Aguado Medical Oncology, Hospital Clínico San Carlos, Madrid, SpainSearch for more papers by this authorP. Ayala de Miguel, P. Ayala de Miguel Medical Oncology, Hospital San Pedro de Alcántara, Caceres, SpainSearch for more papers by this authorI. Navarro-Navarro, I. Navarro-Navarro Dermatology, Hospital Universitario Puerta del Mar, Cádiz, SpainSearch for more papers by this authorE. Masferrer, E. Masferrer Dermatology, Hospital Universitari Mútua Terrassa, Barcelona, SpainSearch for more papers by this authorM. Delgado, M. Delgado Medical Oncology, Hospital Universitario Clínico San Cecilio, Granada, SpainSearch for more papers by this authorL. Bellido-Hernández, L. Bellido-Hernández Medical Oncology, Complejo Asistencial Universitario de Salamanca, Salamanca, SpainSearch for more papers by this authorO. Sanmartin, O. Sanmartin Dermatology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, SpainSearch for more papers by this author First published: 03 February 2024 https://doi.org/10.1111/jdv.19821Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Open Research DATA AVAILABILITY STATEMENT Raw data will be provided by the corresponding author upon reasonable request. REFERENCES 1Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-update 2023. Eur J Cancer. 2023; 193:113252. 10.1016/j.ejca.2023.113252 CASPubMedGoogle Scholar 2Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018; 379: 341–351. 10.1056/NEJMoa1805131 CASPubMedWeb of Science®Google Scholar 3Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020; 138: 125–132. 10.1016/j.ejca.2020.07.029 CASPubMedWeb of Science®Google Scholar 4Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer. 2021; 157: 250–258. 10.1016/j.ejca.2021.08.018 CASPubMedWeb of Science®Google Scholar 5Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, et al. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI Study Group. Cancers (Basel). 2021; 13: 13. 10.3390/cancers13143547 Web of Science®Google Scholar 6Rohaan MW, Duizer ML, Devriese LA, Wilgenhof S, van Herpen CML, Haanen JBAG. Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands. In: Oncology ESoM, editor. European Society of Medical Oncology (ESMO) 2021 congress. Virtual meeting. 2021. Google Scholar 7Challapalli A, Watkins S, Cogill G, Stewart G, Ellis S, Sykes A, et al. Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme. J Eur Acad Dermatol Venereol. 2022; 36: e590–e592. 10.1111/jdv.18082 CASPubMedWeb of Science®Google Scholar 8Guilherme Rabinowits JH, Park SJ, Khushalani N, Panella T, Ellison DM, Gentry RW, et al. 825P. CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. In: Oncology ESoM, editor. European Society for Medical Oncology (ESMO) 2022. Paris. 2022. Google Scholar 9Averbuch I, Salman S, Shtamper N, Doweck I, Popovtzer A, Markel G, et al. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – a real-world experience from Israel. Front Oncol. 2023; 13:1117804. 10.3389/fonc.2023.1117804 CASPubMedWeb of Science®Google Scholar 10Tiosano A, Ben-Ishai M, Cnaany Y, Markel G, Kurman N, Popovtzer A, et al. Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. Eye (Lond). 2023; 37: 2482–2487. 10.1038/s41433-022-02358-y CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
Publication Year: 2024
Publication Date: 2024-02-03
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot